The NIT1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the human NIT1 gene in the Raji B lymphocyte line. This loss-of-function model is supplied as a heterogeneous pool of edited cells, enabling pooled functional genomics and phenotypic screening without clonal isolation. By targeting NIT1, researchers can investigate its tumor-suppressive functions and interactions within metabolic and apoptotic networks.
The Raji host cell line is an EBV-positive Burkitt??s lymphoma-derived B lymphocyte that maintains key functions such as antibody production, antigen presentation, and adaptive immunity. Its transformed phenotype provides a clinically relevant model for B-cell lymphomagenesis and viral oncogenesis, making it well-suited for dissecting molecular mechanisms in lymphoma and other B-cell malignancies.
NIT1 encodes a nitrilase enzyme that catalyzes the hydrolysis of nitriles such as beta-cyanoalanine to carboxylic acids and ammonia, thereby contributing to metabolic detoxification and cellular nitrogen metabolism. Acting as a putative tumor suppressor, NIT1 binds directly to the fragile histidine triad protein FHIT; this interaction potentiates apoptosis through activation of caspases and release of mitochondrial cytochrome c. Upstream, p53 regulates NIT1 expression in response to DNA damage, linking genomic stress to apoptotic execution. Downstream, the NIT1-FHIT complex facilitates caspase activation, and its disruption blocks apoptosis, leading to unchecked cell proliferation. Representative pathway components include FHIT, beta-cyanoalanine, caspases, and cytochrome c.
Within the Raji B lymphocyte environment, the NIT1 knockout model is highly relevant for studying B-cell lymphomagenesis, as deletions at the FRA3B fragile site are common in Burkitt??s lymphoma and other malignancies. The EBV-positive background of Raji cells may synergize with NIT1 loss to further suppress apoptosis and promote survival signaling, providing a platform to investigate cooperative oncogenic mechanisms. Additionally, this model permits exploration of how NIT1-dependent metabolic detoxification pathways influence transformed B-cell metabolism and tumor progression.
Researchers can apply the NIT1 Knockout Raji Polyclonal Cells in a broad range of assays: co-immunoprecipitation and western blotting to confirm NIT1-FHIT interactions; flow cytometry-based apoptosis and proliferation assays; colony formation and xenograft tumor growth studies for in vitro and in vivo tumorigenicity; and RT-qPCR or immunofluorescence for gene expression analysis. Nitrilase activity assays directly measure enzymatic function, while metabolic detoxification studies and drug response screens are feasible in the B-cell lymphoma context. These polyclonal cells provide a versatile tool for dissecting tumor suppressor networks and evaluating therapeutic targets. For further technical details and customization, please contact Ascent Research.
